Lexicon Pharmaceuticals (LXRX) Competitors

Zenas Biopharma (NASDAQ:ZBIO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Is ZBIO or LXRX more profitable?

Zenas Biopharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Zenas Biopharma's return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Lexicon Pharmaceuticals	-4,109.41%	-107.38%	-64.09%

Does the media refer more to ZBIO or LXRX?

In the previous week, Zenas Biopharma had 30 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 31 mentions for Zenas Biopharma and 1 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.30 beat Zenas Biopharma's score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	31 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer ZBIO or LXRX?

Lexicon Pharmaceuticals received 482 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 64.02% of users gave Lexicon Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Zenas Biopharma	Outperform Votes 2 100.00%	Underperform Votes No Votes
Lexicon Pharmaceuticals	Outperform Votes 484 64.02%	Underperform Votes 272 35.98%

Do analysts prefer ZBIO or LXRX?

Zenas Biopharma currently has a consensus target price of $40.00, indicating a potential upside of 300.80%. Lexicon Pharmaceuticals has a consensus target price of $3.67, indicating a potential upside of 421.28%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Zenas Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lexicon Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Do insiders and institutionals hold more shares of ZBIO or LXRX?

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 6.8% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has higher earnings and valuation, ZBIO or LXRX?

Zenas Biopharma has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Zenas Biopharma is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas Biopharma	$5M	83.43	-$148.39M	-$3.55	-2.81
Lexicon Pharmaceuticals	$31.08M	5.57	-$177.12M	-$0.64	-1.10

Summary

Zenas Biopharma and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.